Alirocumab is an injectable treatment for elevated blood cholesterol. The hypothesis of this
study is that it also increases cholesterol excretion from the body into the stool, a process
sometimes called reverse cholesterol transport. A cholesterol metabolic study will be done
before and after 6 weeks of alirocumab treatment. If alirocumab increases reverse cholesterol
transport, it is possible that this action provides additional protection from cardiovascular
disease.